Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treacilil plus first-line immunotherapy and chemotherapy for metastatic or recurrent esophageal squamous cell carcinoma
ChiCTR2400086859Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Incidence of grade >=3 neutropenia during chemotherapy. Started Jul 2024; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400086859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086859.